The PE Ratio as of September 2024 (TTM) for Viracta Therapeutics, Inc. (VIRX) is -0.20

According to Viracta Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.20. This represents a change of -72.46% compared to the average of -0.73 of the last 4 quarters.

Viracta Therapeutics, Inc. (VIRX) Historical PE Ratio (quarterly & annually)

How has VIRX PE Ratio performed in the past?

The mean historical PE Ratio of Viracta Therapeutics, Inc. over the last ten years is -2.18. The current -0.20 PE Ratio has changed 815.45% with respect to the historical average. Over the past ten years (40 quarters), VIRX's PE Ratio was at its highest in in the December 2023 quarter at -0.40. The PE Ratio was at its lowest in in the December 2014 quarter at -86.30.

Viracta Therapeutics, Inc. (VIRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Viracta Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Viracta Therapeutics, Inc. (VIRX) Average PE Ratio

How has VIRX PE Ratio performed in the past?

The current PE Ratio of Viracta Therapeutics, Inc. (VIRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Viracta Therapeutics, Inc. (VIRX) PE Ratio vs. Peers

How is VIRX’s PE Ratio compared to its peers?

Viracta Therapeutics, Inc.’s PE Ratio is greater than Vincerx Pharma, Inc. (-0.93), less than TRACON Pharmaceuticals, Inc. (0.03), greater than Rallybio Corporation (-0.66), greater than Tenaya Therapeutics, Inc. (-1.41), less than Lyra Therapeutics, Inc. (-0.18), greater than Trevi Therapeutics, Inc. (-9.15), greater than SQZ Biotechnologies Company (-3.78), greater than Protara Therapeutics, Inc. (-0.98), greater than ALX Oncology Holdings Inc. (-0.66), greater than Cabaletta Bio, Inc. (-2.17), greater than EyePoint Pharmaceuticals, Inc. (-5.42), greater than Biomea Fusion, Inc. (-2.06), less than X4 Pharmaceuticals, Inc. (7.53), greater than Mereo BioPharma Group plc (-18.94), greater than Inozyme Pharma, Inc. (-4.19), greater than Terns Pharmaceuticals, Inc. (-7.31), greater than Leap Therapeutics, Inc. (-1.96), greater than Bicycle Therapeutics plc (-7.85), greater than IGM Biosciences, Inc. (-4.34), greater than Monte Rosa Therapeutics, Inc. (-3.07), greater than Stoke Therapeutics, Inc. (-7.93),

Build a custom stock screener for Viracta Therapeutics, Inc. (VIRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viracta Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viracta Therapeutics, Inc. (VIRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viracta Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.